Health care stocks retreated late Friday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.3%.
The iShares Biotechnology ETF (IBB) was down 0.1%.
In corporate news, Vivos Therapeutics (VVOS) shares jumped 9% after the company said it issued a $1.1 million convertible promissory note to V-Co Investors 2, with proceeds to be used for the acquisition of The Sleep Center of Nevada.
Bicara Therapeutics (BCAX) shares fell 43% after the company said late Thursday that its latest trial for a potential head and neck cancer treatment has yet to reach median overall survival.
Merus (MRUS) shares surged 32% after the company reported favorable interim cancer trial results in the previous day.
Imunon (IMNN) shares rallied 175%. It reported positive data showing an improvement in overall and progression-free survival from a phase 2 trial of IMNN-001 in ovarian cancer.
Fulcrum Therapeutics (FULC) shares gained 5% after Leerink upgraded the stock to outperform from market perform and raised its price target to $12 from $4.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.